The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     
 


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hartemann-Heurtier, A.
Right arrow Articles by Liblau, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hartemann-Heurtier, A.
Right arrow Articles by Liblau, R. S.
The Journal of Immunology, 2004, 172: 915-922.
Copyright © 2004 by The American Association of Immunologists

An Altered Self-Peptide with Superagonist Activity Blocks a CD8-Mediated Mouse Model of Type 1 Diabetes1

Agnès Hartemann-Heurtier*,{dagger}, Lennart T. Mars*,{ddagger}, Nadège Bercovici2,*, Sabine Desbois*,{ddagger}, Christophe Cambouris2,*, Eliane Piaggio*,{ddagger}, Jacques Zappulla*,{ddagger}, Abdelhadi Saoudi{ddagger} and Roland S. Liblau3,*,{ddagger}

* Institut National de la Scientifique et de la Santé Recherche Médicale Unité 546, Faculté de Médecine Pitié-Salpêtrière, Paris, France; {dagger} Department of Diabetology and Metabolism, Pitié-Salpêtrière Hospital, Paris, France; and {ddagger} Institut National de la Scientifique et de la Santé Recherche Médicale Unité 563, Purpan Hospital, Toulouse, France

T cell tolerance can be experimentally induced through administration of self-peptides with single amino acid substitution (altered peptide ligands or APLs). However, little is known about the effects of APLs on already differentiated autoreactive CD8+ T cells that play a pivotal role in the pathogenesis of autoimmune diabetes. We generated a panel of APLs derived from an influenza virus hemagglutinin peptide exhibiting in vitro functions ranging from antagonism to superagonism on specific CD8+ T cells. A superagonist APL was further characterized for its therapeutic activity in a transgenic mouse model of type 1 diabetes. When injected i.v. 1 day after the transfer of diabetogenic hemagglutinin-specific CD8+ T cells into insulin promoter-hemagglutinin transgenic mice, the superagonist APL proved more effective than the native hemagglutinin peptide in blocking diabetes. This protective effect was associated with an inhibition of CD8+ T cell cytotoxicity in vivo and with a decreased accumulation of these cells in the pancreas, leading to a marked reduction of intrainsulitis. In conclusion, a superagonist "self-peptide" APL was more effective than the native peptide in treating a CD8+ T cell-mediated diabetes model.




This article has been cited by other articles:


Home page
J. Immunol.Home page
W. Zang, M. Lin, S. Kalache, N. Zhang, B. Kruger, A. M. Waaga-Gasser, M. Grimm, W. Hancock, P. Heeger, B. Schroppel, et al.
Inhibition of the Alloimmune Response through the Generation of Regulatory T Cells by a MHC Class II-Derived Peptide
J. Immunol., December 1, 2008; 181(11): 7499 - 7506.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. A. Wasserman and B. D. Evavold
Induction of Anergy by Antibody Blockade of TCR in Myelin Oligodendrocyte Glycoprotein-Specific Cells
J. Immunol., June 1, 2008; 180(11): 7259 - 7264.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
S. Mostbock, S. Vidal, J. Schlom, and H. Sabzevari
Enhanced Levels of Costimulation Lead to Reduced Effector/Memory CD8+ T Cell Functionality
J. Immunol., September 15, 2007; 179(6): 3524 - 3534.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. Blancou, R. Mallone, E. Martinuzzi, S. Severe, S. Pogu, G. Novelli, G. Bruno, B. Charbonnel, M. Dolz, L. Chaillous, et al.
Immunization of HLA Class I Transgenic Mice Identifies Autoantigenic Epitopes Eliciting Dominant Responses in Type 1 Diabetes Patients
J. Immunol., June 1, 2007; 178(11): 7458 - 7466.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
T. Kinnunen, W. W. Kwok, A. Narvanen, M. Rytkonen-Nissinen, A. Immonen, S. Saarelainen, A. Taivainen, and T. Virtanen
Immunomodulatory potential of heteroclitic analogs of the dominant T-cell epitope of lipocalin allergen Bos d 2 on specific T cells
Int. Immunol., December 1, 2005; 17(12): 1573 - 1581.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Immonen, S. Farci, A. Taivainen, J. Partanen, S. Pouvelle-Moratille, A. Narvanen, T. Kinnunen, S. Saarelainen, M. Rytkonen-Nissinen, B. Maillere, et al.
T Cell Epitope-Containing Peptides of the Major Dog Allergen Can f 1 as Candidates for Allergen Immunotherapy
J. Immunol., September 15, 2005; 175(6): 3614 - 3620.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Griseri, L. Beaudoin, J. Novak, L. T. Mars, F. Lepault, R. Liblau, and A. Lehuen
Invariant NKT Cells Exacerbate Type 1 Diabetes Induced by CD8 T Cells
J. Immunol., August 15, 2005; 175(4): 2091 - 2101.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. S. Patke and D. L. Farber
Modulation of Memory CD4 T Cell Function and Survival Potential by Altering the Strength of the Recall Stimulus
J. Immunol., May 1, 2005; 174(9): 5433 - 5443.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 2004 by The American Association of Immunologists, Inc. All rights reserved.